Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "in explicit technical detail"

It is interesting to note that the fiscal year for both Toshiba and Matsushita ends March 31, 2008, I believe. So a possibility that they wanted to defer any payments until the new fiscal year starting April 1st.

And, given what has transpired with the exchange rate, perhaps Js would have wanted a yen royalty. We get USD based on the current exchage rate. Which would further obscure what they are paying. But then, doesn't PTSC have to tell shareholder's at least that revenue recognition has changed, or they expect royalty payments in the future? Not how much, or from whom, but just that the situation exists? This is why I keep thinking in terms of business resolution meaning just that. Opty

Share
New Message
Please login to post a reply